The short version of lyophilization fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-28 and is reviewed periodically as new material appears.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
| Property | Value | Notes |
|---|---|---|
| Route studied | Intranasal | Predominant route in published reports |
| Circulation stability | Short, minutes scale | Peptidases cleave it; the tail slows the process |
| Analytical method | RP-HPLC with mass spectrometry | Used for identity and purity assessment |
| Reported outcome domains | Anxiety and cognitive measures | Derived from small, mostly regional trials |
| Regulatory status | Marketed in Russia | Availability outside that market is limited |
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
The oubli plant (from which the protein was isolated) grows in Gabon and Cameroon where its fruit has been consumed by apes and local people over history. Due to brazzein and pentadin, the berries of the plant have exceptional sweetness. Locals call the berries "oubli" (French for "forgot") in their vernacular language because their taste is said to encourage nursing infants to forget their mother's milk, as once babies eat them, they may forget to return to their mothers.
==== Metabolism ==== Sertraline is subject to extensive first-pass metabolism, as indicated by a small study of radiolabeled sertraline in which less than 5% of plasma radioactivity was unchanged sertraline in two males. The principal metabolic pathway for sertraline is N-demethylation into desmethylsertraline (N-desmethylsertraline) mainly by CYP2B6. Reduction, hydroxylation, and glucuronide conjugation of both sertraline and desmethylsertraline also occur. Desmethylsertraline, while pharmacologically active, is substantially (50-fold) weaker than sertraline as a serotonin reuptake inhibitor and its influence on the clinical effects of sertraline is thought to be negligible. Based on in vitro studies, sertraline is metabolized by multiple cytochrome 450 isoforms; however, it appears that in the human body CYP2C19 plays the most important role, followed by CYP2B6. In addition to the cytochrome P450 system, sertraline can be oxidatively deaminated in vitro by monoamine oxidases; however, this metabolic pathway has never been studied in vivo.
== Medical use == According to phase III randomized trials, a cangrelor–clopidogrel combination is safe and has been found to be more effective than standard clopidogrel treatment at reducing ischemic events in the heart, without increasing major bleeding in the treatment of stenotic coronary arteries. The advantages of this drug combination are most prominent in patients with myocardial infarction. Available antiplatelet drugs have delayed onset and offset of action. Since cangrelor's effects are immediate and quickly reversed, it is a more desirable drug for elective treatment of stenotic coronary arteries, high risk acute coronary syndromes treated with immediate coronary stenting, and for bridging those surgery patients who require P2Y12 inhibition. Evidence regarding cangrelor therapy is limited by the lack studies assessing cangrelor administration in conjunction with either prasugrel or ticagrelor. Cangrelor been approved for adults undergoing percutaneous coronary intervention (PCI).
Two issues with self-medication are the lack of knowledge of the public on the dangerous effects of certain antimicrobials (for example ciprofloxacin which can cause tendonitis, tendon rupture and aortic dissection) and broad microbial resistance and when to seek medical care if the infection is not clearing. To determine the public's knowledge and preconceived notions on antibiotic resistance, a screening of 3,537 articles published in Europe, Asia, and North America was done. Of the 55,225 total people surveyed in the articles, 70% had heard of antibiotic resistance previously, but 88% of those people thought it referred to some type of physical change in the human body.
Sources: en.wikipedia.org
==== Starch-based adhesives ==== Starch pastes can be applied with cold lining techniques, which are preferred over heat and pressure-based methods when dealing with degraded or fragile fibers. Carbohydrate-based adhesives are often made from wheat starch and arrowroot/sodium alginate. They are frequently used with Japanese scrolls and panels due to material compatibility and coherence with traditional techniques.
28 December Storm Gerrit: Almost 8,000 homes are still without power after blizzards and flooding in Scotland. Three men die after a four by four goes into the River Esk in North Yorkshire. The UK Health Security Agency says that at least 30 cases of E.coli may be linked to cheese brands recalled on Christmas Day. Confidential papers released by the UK government show that former prime minister Tony Blair was keen for an English Premiership football club to move to Belfast, because he felt it would be a "significant breakthrough if Belfast had a football team playing in the English Premier League". Discussions were also held in the 1990s about relocating Wimbledon F.C. to Belfast because Wimbledon needed to move from its Plough Lane stadium as a result of the findings of the Taylor Report into the Hillsborough disaster. It was suggested the club could be renamed Belfast United. 29 December BBC News reports that a person has died in Scotland following an E.coli outbreak linked to cheese. Newly released government documents from 2003 show that then-Prime Minister Tony Blair was presented with measures to tackle immigration that included constructing a detention camp on the Isle of Mull and breaking international law. 2024 New Year Honours: Those recognised include Alexander McCall Smith (KBE), Tim Martin (KBE), Stuart Broad (CBE), Sir Ridley Scott (GBE), Shirley Bassey (CH), Michael Eavis (KBE), Jilly Cooper (DBE), Sajid Javid (KBE), Margaret Beckett (DBE), Mary Earps (MBE), Emilia Clarke (MBE), Millie Bright (OBE) and Leona Lewis (OBE).
John Scott Award, created in 1816 as the John Scott Legacy Medal and Premium, is presented to people whose inventions are deemed to have improved the "comfort, welfare, and happiness of human kind" in a significant way. Since 1919 the Board of Directors of City Trusts of Philadelphia provide this award, recommended by an advisory committee.
Carnation Evaporated Milk (now owned by Nestlé and licensed to Smuckers in Canada) Dairy Isle (Canada by ADL) PET Evaporated Milk (now owned by Smuckers) Magnolia evaporated milk - (now produced by Eagle Family Foods ) Viking Melk (Norway) - invented by Olav Johan Sopp in 1891, a Nestlé brand since 1897 F&N Evaporated Milk California Farms Evaporated Milk Rainbow Milk, a brand of Royal Friesland Foods Nordmilch AG (Now DMK Deutsches Milchkontor) - Germany Jerzee Evaporated Milk (purchased in 2006 from Diehl Food Products) O-AT-KA Evaporated Milk Ferdi Evaporated Milk (Malaysia) Vitalait Evaporated Milk (Senegal) Luna Evaporated Milk (Saudi Arabia) Gloria Evaporated Milk (Peru)
== Interactions == GSTP1 has been shown to interact with Fanconi anemia, complementation group C and MAPK8. GST-Pi is expressed in many human tissues, particularly in the biliary tree, renal distal convoluted tubules and lungs.
Sources: en.wikipedia.org
The drug must be found to be effective against the disease for which it is seeking approval (where 'effective' means only that the drug performed better than placebo or competitors in at least two trials). The drug must meet safety criteria by being subject to animal and controlled human testing. Gaining FDA approval usually takes several years. Testing done on animals must be extensive and must include several species to help in the evaluation of both the effectiveness and toxicity of the drug. The dosage of any drug approved for use is intended to fall within a range in which the drug produces a therapeutic effect or desired outcome. The safety and effectiveness of prescription drugs in the U.S. are regulated by the federal Prescription Drug Marketing Act of 1987. The Medicines and Healthcare products Regulatory Agency (MHRA) has a similar role in the UK. Medicare Part D is a prescription drug plan in the U.S. The Prescription Drug Marketing Act (PDMA) is an act related to drug policy. Prescription drugs are drugs regulated by legislation.
KALYANKAR GD, MEISTER A (1959). "Enzymatic synthesis of carnosine and related beta-alanyl and gamma-aminobutyryl peptides". J. Biol. Chem. 234 (12): 3210–8. doi:10.1016/S0021-9258(18)69651-6. PMID 14404206. Stenesh JJ; Winnick T (1960). "Carnosine–anserine synthetase of muscle. 4. Partial purification of the enzyme and further studies of β-alanyl peptide synthesis". Biochem. J. 77 (3): 575–581. doi:10.1042/bj0770575. PMC 1205078. PMID 16748858.
=== Geriatrics === Most antidepressants, including SNRIs, are safe and effective in the geriatric population. The geriatric population is at greater risk for adverse effects relating to drug interaction as they are more likely to experience polypharmacy. Decisions are often based on co-morbid conditions, drug interactions, and patient tolerance. Due to differences in body composition and metabolism, starting doses are often half that of the recommended dose for younger adults. Studies show that these factors also put the geriatric population at increased risk of adverse effects when treated with SNRIs but not with SSRIs.
In 2017, the US Food and Drug Administration (FDA) approved pembrolizumab for any unresectable or metastatic solid tumor with certain genetic anomalies (mismatch repair deficiency or microsatellite instability). This was the first time the FDA approved a cancer drug based on tumor genetics rather than tissue type or tumor site; therefore, pembrolizumab is a so-called tissue-agnostic drug. In the European Union, pembrolizumab is indicated for:
BioShock is a first-person shooter with role-playing customization and stealth elements, and is similar to System Shock 2. The player takes the role of silent protagonist Jack as he is guided through Rapture towards various objectives. The player battles enemies using a combination of traditional weaponry and magic-like plasmids. Aside from the wrench, a melee weapon, players can upgrade their weapons through upgrade stations scattered across the environment; these upgrades modify weapons with added range, lessened recoil, or similar improvements. Weapons can also be equipped with different ammo types to increase effectiveness against varied targets. Plasmids confer superpowers such as casting fire or electric attacks, and in some cases can be used to access new areas—for example, melting ice blocking a path, or tripping the electric lock to open a door. Using plasmids requires EVE—the equivalent of mana—which can be replenished with EVE hypos or certain consumable food and drink. The player has a health meter that decreases when they take damage. The player can restore their health with food or medical packs found throughout Rapture. If the player's health is reduced to zero, they will respawn at a nearby Vita-Chamber, a device that functions as a checkpoint system. A patch for the game allows the Vita-Chambers to be turned off, requiring players to restart a saved game if the character dies.
Sources: en.wikipedia.org
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.
Intranasal delivery is the route described in most published work. It is used because the peptide is degraded quickly once it reaches circulation. Direct evidence of brain penetration in humans is lacking.
Most trials are small, regionally concentrated, and often lack rigorous blinding or placebo control. Independent replication is limited. Reviews in English generally rate the evidence as preliminary.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.